CORDIS
EU research results

CORDIS

English EN
Solid Catalysts for activation of aromatic C-H bonds

Solid Catalysts for activation of aromatic C-H bonds

Objective

Objectives
The H-CCAT project designs, upscales and shapes hybrid catalysts for the C-H functionalization of aromatic compounds. These solid catalysts will possess better recoverability, higher turnover numbers and better selectivity than current homogeneous catalysts for these reactions. The solid catalysts are applied at demonstration scale in the step-economical production of arylated or alkenylated aromatics, yielding motifs of active pharmaceutical ingredients.
Methodology
We will design heterogeneous hybrid catalysts featuring deactivation-resistant active sites, based on N-heterocyclic carbenes (NHCs) or diimine ligands and active metal ions. Via efficient, one-step protocols based on self-assembly, these sites will be embedded in robust porous hybrid materials like hybrid silica or metal-organic frameworks. Deactivation or metal aggregation will be prevented by site isolation or by efficient metal reoxidation (for the oxidative alkenylations). Metal leaching is precluded by using strong bonds between metals and embedded ligands like NHCs. Flow protocols will be designed to maximize the turnover numbers. Catalyst synthesis will be scaled up to kg scale, using efficient one-step protocols, minimizing use of solvents or waste formation. Soft shaping methods, e.g. spray drying, will preserve porosity and activity of the hybrid solids. A demonstration is conducted at minipilot scale at the J&J site (Belgium), allowing LCA analysis, techno-economic assessment and elaboration of the business plan.
Relevance to work program
The catalysts feature new, deactivation resistant active sites; their TOF/TON is maximized by an appropriate porous structure which even can be swelling. Catalysts are produced using innovative one-step protocols to form porous hybrid catalysts as powders or even immediately as shaped objects. The molecules targeted have strong biological and pharmaceutical relevance; they target diseases like influenza, cancer or HIV (case study: Rilpivirine).
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

KATHOLIEKE UNIVERSITEIT LEUVEN

Address

Oude Markt 13
3000 Leuven

Belgium

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 547 600

Participants (9)

Sort alphabetically

Sort by EU Contribution

Expand all

UNIVERSITA DEGLI STUDI DI PERUGIA

Italy

EU Contribution

€ 502 075

GEORG-AUGUST-UNIVERSITAT GOTTINGENSTIFTUNG OFFENTLICHEN RECHTS

Germany

EU Contribution

€ 508 750

AXEL'ONE

France

EU Contribution

€ 436 517,50

JOHNSON MATTHEY PLC

United Kingdom

EU Contribution

€ 520 667,50

FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.

Germany

EU Contribution

€ 499 956,25

JANSSEN PHARMACEUTICA NV

Belgium

EU Contribution

€ 1 019 475

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS

France

EU Contribution

€ 1 580 493,75

SIKEMIA

France

EU Contribution

€ 404 375

PROFMOF AS

Norway

EU Contribution

€ 568 402,50

Project information

Grant agreement ID: 720996

Status

Ongoing project

  • Start date

    1 January 2017

  • End date

    31 December 2020

Funded under:

H2020-EU.2.1.3.

  • Overall budget:

    € 7 588 312,50

  • EU contribution

    € 7 588 312,50

Coordinated by:

KATHOLIEKE UNIVERSITEIT LEUVEN

Belgium